Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells

Neurological Research

Volumn 27, Issue 8, 2005, Pages 797-800

  Cuevas, Pedro ^a,c   Diaz Gonzalez D ^a   Gimenez Gallego G ^b   Dujovny, M ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Dobesilate; Glioma cells; Proliferation

Indexed keywords

CRYSTAL VIOLET; DOBESILATE CALCIUM; FIBROBLAST GROWTH FACTOR;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC VEIN INSUFFICIENCY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG INDICATION; GLIOMA CELL; IC 50; INCUBATION TIME; NICK END LABELING; NONHUMAN; RAT; STAINING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CALCIUM DOBESILATE; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; INHIBITORY CONCENTRATION 50; RATS;

EID: 25444530122     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X63665     Document Type: Article

References (29)

1. Counsell CE, Grant R. Incidence of primary and secondary intracranial tumors: A systematic review of their methodology and results. J Neurooncol 1998; 37: 341-350
2. Castro MG, Cowen K, Willianson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71-108
3. Louis DN, Pomeroy SL, Caircross JQ. Focus on central nervous system neoplasia. Cancer Cell 2002; 1: 125-128
4. Auguste P, Gursel DB, Lemière S, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both, angiogenesis-dependent and independent mechanisms. Cancer Res 2001; 61: 1717-1726
5. Jansen M, de Witt Hamer PC, Witmer AN, et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 2004; 45: 143-163
6. Kaur B, Tan C, Brat DJ, et al. Genetic and hypoxic regulation of angiogenesis in gliomas. j Neurooncol 2004; 70: 229-243
7. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Bioche Biophys Res Commun 2000; 277: 494-498
8. The ADHR consortium. Autosomal dominant hypophosphatemic reckets is associated with mutations in fgf23. Nat Genet 2000; 26: 345-348.
9. Giménez-Gallego G, Cuevas P. Fibroblast growth factors, proteins with a broad spectrum of biological activities. Neurol Res 1994; 16:313-316
10. Thomas KA, Giménez-Gallego G. Fibroblast growth factors: Broad spectrum mitogens with potent angiogenic activity. Trends Biochem Sci 1986; 11: 1-4
11. Gross JL, Morrison RS, Eidsvoog K, et al. Basic fibroblast growth factor: a potential autocrine regulator of human glioma cell growth. J Neurosci Res 1990; 27: 689-696
12. Cristofori G. The role of fibroblast growth factor during tumor progression and angiogenesis, Oxford, UK: Oxford University Press, 1998: pp. 201-238
13. Cuevas P, Reimers D, Díaz-González D, et al. Apoptosis of glioma cells induced by the fibroblast growth factor inhibitor 1,3,6-naphthalenesulfonate. Neurosci Lett 1999; 275: 149-151
14. Pesenti E, Sola F, Mongelli N, et al. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992; 66: 367-372
15. Cuevas P, Carceller F, Díaz-González D, et al. Inhibition of rat glioma growth by neomycin. Preliminary report. Neurol Res 2002; 24: 522-524
16. Tejerina T, Ruiz E. Calcium dobesilate: Pharmacology and future approaches. Gen Pharmac 1998; 131: 357-360
17. Lameynardie S, Chiavaroli C, Travo P, et al. Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 2005; 510: 149-156
18. Cuevas P, Arrazola MJ. Treatment of basal cell carcinoma with topical dobesilate. J Am Acad Dermatol 2005; 53: 526-527
19. Cuevas P, Arrazola JM. Dobesilate in the treatment of plaque psoriasis. Eur J Med Res 2005; 10: 373-376
20. Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res (in press)
21. Cuevas P, Sánchez I, Lozano RM, et al. Dobesilate is an angiogenesis inhibitor. Eur J Med Res 2005; 10: 369-372
22. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30: 133-142
23. Lozano RM, Jiménez MA, Santoro J, et al. Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalene trisulfonate: A minimal model for the anti-tumoral action of suramins and suradistas. J Mol Biol 1998; 281: 899-915
24. Cuevas P, Lozano RM, Giménez-Gallego G. Suppression of acidic fibroblast growth factor-dependent angiogenesis by the antigrowth activity of 1,3,6-naphthalene trisulphonate. Neurol Res 1999; 21: 191-194
25. Cuevas P, Carceller F, Reimers D, et al. Inhibition of intra-tumoral angiogenesis and glioma growth by the fibroblast growth factor inhibitor 1,3,6-naphthalenetrisulfonate. Neurol Res 1999; 21: 481-487
26. Cuevas P, Reimers D, Díaz D, et al. Apoptosis of glioma cells induced by the fibroblast growth factor inhibitor 1,3,6-naphthalenetrisulfonate. Neurosc Lett 1999; 275: 149-151
27. Cuevas P, Carceller F, Díaz D, et al. Abolished angiogenicity and tumorigenicity of rat glioma by 1-naphthalenemonosulfonate. Neurosc Lett 2001; 308: 185-188
28. Fernández-Tornero C, Lozano RM, Redondo-Horcajo M, et al. Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalenesulfonate. J Biol Chem 2003; 278: 21774-21781
29. Manetti F, Corelli F, Botta M. Fibroblast growth factors and their inhibitors. Curr Pharm Des 2000; 6: 1897-1924